内部控制审计报告 浙江我武生物科技股份有限公司 容诚审字[2025]200Z0640号 ) 容诚会计师事务所(特殊普通合伙 中国·北京 内部控制审计报告 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 容诚审字[2025]200Z0640号 浙江我武生物科技 股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了浙江我武生物科技股份有限公司（以下简称"我武生物"）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是我武 生物董事会的责任。 我们认为，我武生物于 2024 年 12 月 31 日按照《企业内部控制基本规范》 ...

浙江我武生物科技股份有限公司 容诚专字[2025]200Z0310号 ) 容诚会计师事务所(特殊普通合伙 中国·北京 往来情况专项说明 非经营性资金占用及其他关联资金 关于浙江我武生物科技股份有限公司 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 非经营性资金占用及其他关联资金往来情况专项说明 容诚专字[2025]200Z0310号 浙江我武生物科技股份有限公司 全体股东： 我们接受委托，依据中国注册会计师审计准则审计了浙江我武生物科技股份 有限公司（以下简称"我武生物"）2024 年 12 月 31 日的合并及母公司资产负债 表，2024 年度的合并及母公司利润表、合并及母公司现金流量表和合并及母公司 所有者权益变动表以及财务报表附注，并于 2025 年 4 月 18 日出具了容诚审字 [2025]200Z0118 号的无保留意 ...

Group 1 - The company reported a revenue of 228 million yuan for the first quarter of 2025, representing a year-on-year increase of 5.65% [1] - The net profit for the same period was 74.34 million yuan, showing a year-on-year decrease of 3.71% [1]

浙江我武生物科技股份有限公司 独立董事 2024 年度述职报告 张飞达（ZHANG FEIDA） 各位股东及股东代表： 作为浙江我武生物科技股份有限公司（以下简称"公司"）的独立董事，根 据《公司法》、《证券法》、《上市公司治理准则》、中国证券监督管理委员会 《上市公司独立董事管理办法》等有关法律、法规以及《公司章程》、《独立董 事制度》等公司制度的规定，我在 2024 年度工作中，定期了解、检查公司经营 情况，认真履行了独立董事的职责，恪尽职守，勤勉尽责，积极出席相关会议， 参与各议题的讨论并提出合理建议，出席董事会专门委员会会议，充分发挥独立 董事作用，维护公司整体利益和全体股东特别是中小股东的合法权益。根据深圳 证券交易所《上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有 关要求，现将 2024 年度独立董事职责履行情况报告如下： 一、 基本情况 张飞达（ZHANG FEIDA），1980 年出生，男，澳大利亚国籍，会计学博士。 历任中山大学管理学院助理教授、莫道克大学博士生导师、MBA 中心主任，昆 士兰大学副教授、博士生导师。曾获"闽江学者讲座教授"、"美国会计学年会 最佳论文奖"、" ...

浙江我武生物科技股份有限公司 信息披露暂缓与豁免管理制度 （2025 年 4 月） 第一章 总 则 第一条 为规范浙江我武生物科技股份有限公司（以下简称"公司"）信息 披露暂缓与豁免业务行为，确保公司及相关信息披露义务人依法合规地履行信息 披露义务，保护投资者的合法权益，根据《中华人民共和国公司法》、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司信息披露管理办法》、《深 圳证券交易所创业板股票上市规则》（以下简称"《上市规则》"）、以及有关法 律、行政法规、规章和《浙江我武生物科技股份有限公司章程》（以下简称"《公 司章程》"）、《浙江我武生物科技股份有限公司信息披露事务管理制度》（以下 简称"《信息披露事务管理制度》"）的规定，结合公司信息披露工作的实际情 况，制定本制度。 第二条 公司及相关信息披露义务人暂缓、豁免披露临时报告，在定期报告、 临时报告中豁免披露中国证券监督管理委员会和深圳证券交易所规定或者要求 披露的内容，适用本制度。 第三条 公司及相关信息披露义务人应当真实、准确、完整、及时、公平地 披露信息，不得滥用暂缓或者豁免披露规避信息披露义务、误导投资者，不得实 施内幕交易、操 ...

浙江我武生物科技股份有限公司 我已对本人的独立性情况进行自查，并将《独立董事独立性自查情况表》 提交董事会。报告期内，我作为公司独立董事任职符合法律法规和规范性文件 等规定的独立性要求，不存在影响独立性的情况。 二、 年度履职概况 1、 出席董事会和股东大会会议情况 报告期内，我出席董事会和股东大会会议具体情况如下： 独立董事 2024 年度述职报告 徐国良 各位股东及股东代表： 作为浙江我武生物科技股份有限公司（以下简称"公司"）的独立董事，根 据《公司法》、《证券法》、《上市公司治理准则》、中国证券监督管理委员会 《上市公司独立董事管理办法》等有关法律、法规以及《公司章程》、《独立董 事制度》等公司制度的规定，我在 2024 年度工作中，定期了解、检查公司经营 情况，认真履行了独立董事的职责，恪尽职守，勤勉尽责，积极出席相关会议， 参与各议题的讨论并提出合理建议，出席董事会专门委员会会议，充分发挥独立 董事作用，维护公司整体利益和全体股东特别是中小股东的合法权益。根据深圳 证券交易所《上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有 关要求，现将 2024 年度独立董事职责履行情况报告如下： ...

内部审计制度 （2025 年 04 月） 第一章 总 则 第一条 为了规范浙江我武生物科技股份有限公司（以下简称"公司"）内部 审计工作，建立健全内部审计制度，提升内部审计工作质量，充分发挥内部审计 在强化内部控制、改善经营管理、提高经济效益中的作用，促进公司经营效率、 经济效益的提高，确保内部控制持续有效实施，维护投资者的权益，实现内部审 计的制度化和规范化，根据《中华人民共和国公司法》、《中华人民共和国证券法》、 《中华人民共和国审计法》、《中华人民共和国审计法实施条例》、《深圳证券交易 所创业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》、《浙江我武生物科技股份有限公司章程》（以下简称"《公 司章程》"）等有关规定，结合公司实际情况，制定本制度。 第二条 本制度适用于浙江我武生物科技股份有限公司（含分公司）、子公司 （含分公司）等合并报表范围内的公司（以下简称"所属公司"）内部审计管理。 第三条 本制度所称内部审计，是公司内部独立、客观的保证与咨询活动， 通过系统化、规范化的方法，对公司财务收支、业务活动、内部控制、风险管理、 财务信息实施独立、客观的监督 ...

经核查独立董事徐国良、张飞达（ZHANG FEIDA）的任职经历以及其签署 的相关自查文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公 司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他 可能妨碍其进行独立客观判断的关系。因此，公司独立董事符合中国证监会《上 市公司独立董事管理办法》、深圳证券交易所《上市公司自律监管指引第 2 号— —创业板上市公司规范运作》中对独立董事独立性的相关要求。 浙江我武生物科技股份有限公司 董事会对独立董事 2024 年度独立性自查情况的专项意见 根据中国证监会《上市公司独立董事管理办法》、深圳证券交易所《上市公 司自律监管指引第 2 号——创业板上市公司规范运作》等要求，浙江我武生物科 技股份有限公司（以下简称"公司"）董事会就公司在任独立董事徐国良、张飞 达（ZHANG FEIDA）的独立性情况进行评估并出具如下意见： 浙江我武生物科技股份有限公司董事会 2025 年 4 月 18 日 ...

Financial Performance - The company's operating revenue for 2024 reached ¥925,394,524.96, representing a 9.10% increase compared to ¥848,190,443.30 in 2023[27]. - The net profit attributable to shareholders for 2024 was ¥317,822,381.76, a 2.46% increase from ¥310,184,878.02 in 2023[27]. - The cash flow from operating activities decreased by 31.31% to ¥262,440,005.22 in 2024, down from ¥382,075,662.45 in 2023[27]. - The total assets at the end of 2024 amounted to ¥2,709,124,934.20, reflecting a 5.74% increase from ¥2,562,166,715.87 at the end of 2023[27]. - The company reported a basic earnings per share of ¥0.6070 for 2024, up 2.46% from ¥0.5924 in 2023[27]. - The company’s net profit after deducting non-recurring gains and losses was ¥306,309,299.41 in 2024, a 2.72% increase from ¥298,209,749.14 in 2023[27]. - The weighted average return on equity for 2024 was 13.89%, down from 14.96% in 2023[27]. - The company achieved a revenue of ¥925,394,524.96, representing a year-over-year growth of 9.10%[54]. - The net profit attributable to shareholders was ¥317,822,381.76, reflecting a year-over-year increase of 2.46%[54]. Dividend Distribution - The company plans to distribute a cash dividend of 1.20 RMB per 10 shares to all shareholders, based on a total of 523,584,000 shares[11]. - The company aims to improve human quality of life and extend healthy lifespan, with a goal of distributing over 30% of net profit as cash dividends annually since its listing, totaling over 850 million RMB, equivalent to approximately 4 times the initial fundraising amount[101]. - The company has distributed cash dividends exceeding 850 million RMB since its listing, reflecting its commitment to shareholder returns[101]. - The company plans to distribute cash dividends of ¥1.00 per 10 shares for the first three quarters of 2024, based on a total share capital of 523,584,000 shares[199]. - The cash dividend distribution plan for 2024 has been approved by the board and is in compliance with relevant laws and regulations[172]. Product Development and Innovation - The main product, "Dust Mite Drops," significantly contributes to revenue, indicating a high dependency on this product for profitability[9]. - The company aims to accelerate the promotion of new products like "Artemisia Flower Pollen Sublingual Drops" to diversify its product offerings and reduce concentration risk[10]. - The company is actively expanding into the field of natural medicines, focusing on the discovery of new structures and molecules to combat antibiotic-resistant bacteria, addressing a significant public health challenge[44]. - The company has received approval for three new skin prick test solutions: "Sycamore pollen allergen skin prick solution," "German cockroach allergen skin prick solution," and "cat dander allergen skin prick solution," enhancing its product offerings for allergy diagnosis[46]. - The company is focusing R&D investments on its core business while exploring complementary technologies to maintain competitive advantages in allergy treatment[119]. - The company has initiated clinical trials for new products, including a dermatitis diagnostic patch and a dust mite membrane agent, to address specific allergic conditions[119]. Regulatory Environment and Compliance - Regulatory changes in the pharmaceutical industry are tightening, requiring companies to enhance their quality management systems[5]. - The company is committed to compliance and risk management in response to evolving industry regulations[6]. - The company is facing increasing regulatory scrutiny in the pharmaceutical industry, necessitating a robust quality management system[105]. - The company management will closely monitor industry policy changes to mitigate operational risks[106]. - The NMPA has issued multiple guidelines for stem cell products, indicating a commitment to improving the regulatory environment and quality management in the sector[39][40]. Market Position and Strategy - The company plans to leverage the growing health management services and aging population trends to enhance its market position in the biopharmaceutical industry[36]. - The Chinese pharmaceutical market is experiencing rapid growth, driven by increased policy support, rising disposable income, and improved healthcare infrastructure[37]. - The company remains a leader in the sublingual immunotherapy market, with only its products "Dust Mite Drops" and "Artemisia Pollen Sublingual Drops" approved for nationwide sale[42]. - The company is focused on maintaining stable pricing strategies in response to significant bidding price reductions in certain regions[7]. - The company is committed to maintaining its leading position in the desensitization field while exploring new major medical product areas, such as stem cell therapy and natural drugs[102]. Research and Development - The company achieved a total R&D investment of ¥124,764,619.17, accounting for 13.48% of its operating revenue[60]. - The company has nearly 300 R&D personnel, providing a strong talent reserve for innovation and development[60]. - The company has a robust R&D team focused on biopharmaceuticals, with a complete independent R&D chain[53]. - The company has 12 valid Chinese invention patents and 3 utility model patents, along with 7 foreign invention patents[60]. - The company has developed an allergen skin prick test reading device to improve diagnostic efficiency for allergic diseases[63]. Environmental Compliance - The company strictly adhered to multiple environmental protection laws and industry standards during its operations[182]. - The company has established comprehensive wastewater and waste gas treatment facilities, ensuring that the discharge of pollutants is below the limits set by the pollution discharge permit[190]. - The company reported no exceedances of the major pollutants during the reporting period[185]. - The company has implemented a strict emergency response plan for environmental incidents, which is updated regularly and practiced annually[191]. - The company has engaged third-party qualified units for the operation and maintenance of wastewater and exhaust treatment facilities[195]. Corporate Governance - The company has received an A rating for information disclosure from the Shenzhen Stock Exchange for three consecutive years[125]. - The company’s governance structure includes a board of directors, supervisory board, and various committees to ensure effective operation and risk management[127]. - The company emphasizes compliance and transparency in its operations, ensuring timely and accurate information disclosure to investors[125]. - The company has a well-defined internal management structure that operates independently from the controlling shareholder and its affiliates[139]. - The company has a structured remuneration decision process involving the Compensation and Assessment Committee and the Board of Directors[153].

Core Viewpoint - The article discusses the significant increase in pollen levels in Beijing due to a warm winter, leading to a surge in allergy cases and a corresponding rise in the demand for allergy medications, indicating a booming market for allergy-related pharmaceuticals [1][8][9]. Industry Overview - The allergy medication market in China is projected to experience rapid growth, potentially exceeding $20 billion by 2030, driven by an increasing patient population and rising awareness of allergy conditions [8][9]. - Currently, there are approximately 500 million patients in China suffering from allergic diseases such as allergic rhinitis, asthma, atopic dermatitis, and chronic obstructive pulmonary disease [8]. Market Dynamics - Recent data shows a 40% year-on-year increase in the purchase of allergy-related medications, with a 127% day-on-day increase in orders since March 20 in Beijing [8]. - Popular allergy medications like Loratadine and its upgraded version Desloratadine have seen significant sales growth, with Loratadine's retail market sales surpassing 7.6 billion yuan in the past five years, maintaining an annual growth rate of over 10% [10][11]. Competitive Landscape - The allergy medication market is characterized by numerous players, primarily traditional pharmaceutical companies that have historically relied on generic drugs [10]. - New entrants are focusing on innovative drug development, including small molecule targeted drugs and biological agents, with over 1,600 clinical trials related to allergies registered globally [12][13]. Emerging Trends - A new biological drug, Dupilumab, has been approved for treating seasonal allergic rhinitis, showing promising results in clinical trials [13]. - The high pricing of biological drugs presents a challenge for patient acceptance, as many patients prefer cost-effective options despite the superior efficacy of these new treatments [15]. Treatment Innovations - Desensitization therapy is gaining attention as a long-term solution for allergies, although it requires a lengthy treatment period [16][17]. - Companies like Iwubio are already seeing sales growth in desensitization products, indicating a potential shift in treatment preferences among patients [17]. Future Outlook - The allergy medication market in China is still in its early stages, with many companies vying for a share of this lucrative sector, awaiting the emergence of the next blockbuster product [19].